Блог – PharmCAT.NET

PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Найти:

Свежие записи

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Postmarketing Requirements and Commitments: Searchable Database
Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-31 By FDA
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Revision: 2, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-31
Human medicines European public assessment report (EPAR): Quadramet, samarium [153Sm] lexidronam pentasodium, Date of authorisation: 04/02/1998, Revision: 16, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-31
Human medicines European public assessment report (EPAR): Levetiracetam Hospira, levetiracetam, Date of authorisation: 07/01/2014, Revision: 27, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-31
Biosimilar Product Information
Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-31 By FDA
Human medicines European public assessment report (EPAR): Zurzuvae, zuranolone, Revision: 1, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-31
Human medicines European public assessment report (EPAR): Januvia, sitagliptin, Date of authorisation: 20/03/2007, Revision: 35, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-31
Human medicines European public assessment report (EPAR): Syfovre, pegcetacoplan, Date of refusal: 16/12/2024, Status: Refused
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
Human medicines European public assessment report (EPAR): Puregon, follitropin beta, Date of authorisation: 02/05/1996, Revision: 36, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
Human medicines European public assessment report (EPAR): Elonva, corifollitropin alfa, Date of authorisation: 25/01/2010, Revision: 24, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
Human medicines European public assessment report (EPAR): Teysuno, tegafur,gimeracil,oteracil, Date of authorisation: 14/03/2011, Revision: 24, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Date of authorisation: 17/07/2015, Revision: 67, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-30
Joint US FDA – Health Canada ICH Public Meeting - 02/22/2024
Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-30 By FDA
Biologics Procedures (SOPPs)
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-29 By FDA
OTP Events, Meetings, and Workshops
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-29 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.